STAT3 and breast carcinoma: FLLL32 [(2E,2’E)-1,1’-(cyclohexane-1,1-diyl)bis(3-(3,4-dimethoxyphenyl)prop-2-en-1-one] was designed to preferentially interact with critical domains of JAK2 and STAT3 and demonstrated greater inhibition of STAT3 phosphorylation and its downstream targets in human rhabodomysarcoma cells, human multiple myeloma, glioblastoma, liver cancer, breast cancer, pancreatic cancer, and colorectal cancer cell lines over curcumin [34,35,36].